An open-label, randomized, parallel-group, cohort study to evaluate the safety and efficacy of bimatoprost 0.03% versus bimatoprost 0.01% eye drops in patients with glaucoma

Trial Profile

An open-label, randomized, parallel-group, cohort study to evaluate the safety and efficacy of bimatoprost 0.03% versus bimatoprost 0.01% eye drops in patients with glaucoma

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Dec 2015

At a glance

  • Drugs Bimatoprost (Primary)
  • Indications Glaucoma; Open-angle glaucoma; Pigmentary glaucoma
  • Focus Adverse reactions
  • Most Recent Events

    • 13 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top